News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Submits Applications In Europe For Tiotropium + Olodaterol Respimat® Fixed-Dose Combination In COPD


7/2/2014 10:54:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE) For media outside the US, the UK and Canada. Boehringer Ingelheim today announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). These applications are based on data from the large Phase III TOviTO™ clinical trial programme. Further submissions in additional countries will be announced in due course.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES